'''Iniparib''' ([[International nonproprietary name|INN]],<ref name="INN">{{cite web | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65 | url = http://www.who.int/medicines/publications/druginformation/innlists/RL65.pdf | publisher = World Health Organization | accessdate = 20 December 2016 | page = 68 | date = 2011}}</ref> previously known as '''BSI 201''') was a drug candidate for cancer treatment.  It was originally believed to act as an [[Enzyme inhibitor#Irreversible inhibitors|irreversible inhibitor]] of [[PARP1]] (hence, a [[PARP inhibitor]]) and possibly other enzymes through [[covalent bond|covalent modification]],<ref>[http://www.cancernetwork.com/display/article/10165/1514773 Development of PARP Inhibitors: An Unfinished Story], Jan 2010</ref><ref>http://www.biparsciences.com/000011.html  {{webarchive |url=https://web.archive.org/web/20100623054505/http://www.biparsciences.com/000011.html |date=June 23, 2010 }}</ref> but its effects against PARP were later disproven.<ref>{{cite journal | pmid = 22128301 | year = 2012 | last1 = Liu | first1 = X | last2 = Shi | first2 = Y | last3 = Maag | first3 = DX | last4 = Palma | first4 = JP | last5 = Patterson | first5 = MJ | last6 = Ellis | first6 = PA | last7 = Surber | first7 = BW | last8 = Ready | first8 = DB | last9 = Soni | first9 = NB | last10 = Ladror | first10 = U. S. | last11 = Xu | first11 = A. J. | last12 = Iyer | first12 = R. | last13 = Harlan | first13 = J. E. | last14 = Solomon | first14 = L. R. | last15 = Donawho | first15 = C. K. | last16 = Penning | first16 = T. D. | last17 = Johnson | first17 = E. F. | last18 = Shoemaker | first18 = A. R. | title = Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a Bona Fide PARP inhibitor | volume = 18 | issue = 2 | pages = 510–23 | doi = 10.1158/1078-0432.CCR-11-1973 | journal = Clinical Cancer Research| display-authors = 8 }}</ref><ref>{{cite journal | pmid = 22291137 | year = 2012 | last1 = Patel | first1 = AG | last2 = De Lorenzo | first2 = SB | last3 = Flatten | first3 = KS | last4 = Poirier | first4 = GG | last5 = Kaufmann | first5 = SH | title = Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase in Vitro | volume = 18 | issue = 6 | pages = 1655–62 | doi = 10.1158/1078-0432.CCR-11-2890 | pmc = 3306513 | journal = Clinical Cancer Research}}</ref>  It underwent [[clinical trial]]s for treatment of some types of [[breast cancer]],<ref>[http://www.parp-inhibitors.com/bsi201.html BSI 201]</ref><ref>{{cite news |url=https://www.reuters.com/article/healthNews/idUSTRE54U1FV20090531 |title=New breast cancer drugs block cell repair enzyme | work=Reuters | date=2009-05-31}}</ref> but was discontinued after disappointing phase III clinical trials.
